As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.
18 Analysts have issued a ORIC Pharmaceuticals Inc forecast:
18 Analysts have issued a ORIC Pharmaceuticals Inc forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -148 -148 |
19%
19%
|
|
| EBIT (Operating Income) EBIT | -149 -149 |
19%
19%
|
|
| Net Profit | -138 -138 |
24%
24%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.
| Head office | United States |
| CEO | Jacob Chacko |
| Employees | 115 |
| Founded | 2014 |
| Website | oricpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


